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Abstract
Telethonin is a 19-kDa sarcomeric protein, localized to the Z-disc of skeletal and cardiac muscles. Mutations in the telethonin gene cause
limb–girdle muscular dystrophy type 2G (LGMD2G). We investigated the sarcomeric integrity of muscle fibers in LGMD2G patients,
through double immunofluorescence analysis for telethonin with three sarcomeric proteins: titin, a-actinin-2, and myotilin and observed the
typical cross striation pattern, suggesting that the Z-line of the sarcomere is apparently preserved, despite the absence of telethonin.
Ultrastructural analysis confirmed the integrity of the sarcomeric architecture. The possible interaction of telethonin with other proteins
responsible for several forms of neuromuscular disorders was also analyzed. Telethonin was clearly present in the rods in nemaline myopathy
(NM) muscle fibers, confirming its localization to the Z-line of the sarcomere. Muscle from patients with absent telethonin showed normal
expression for the proteins dystrophin, sarcoglycans, dysferlin, and calpain-3. Additionally, telethonin showed normal localization in muscle
biopsies from patients with LGMD2A, LGMD2B, sarcoglycanopathies, and Duchenne muscular dystrophy (DMD). Therefore, the primary
deficiency of calpain-3, dysferlin, sarcoglycans, and dystrophin do not seem to alter telethonin expression.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The limb–girdle muscular dystrophies (LGMDs) include
a heterogeneous group of progressive disorders mainly
affecting the pelvic and shoulder girdle musculature. The
inheritance may be autosomal dominant (LGMD1) or
recessive (LGMD2). Clinically, it ranges from severe forms
with onset in the first decade and rapid progression, to
milder forms with later onset and slower progression [1,2].
Six autosomal dominant LGMD forms, designated
LGMD1A to LGMD1F, were already mapped respectively
at 5q22–q34 (myotilin) [3,4]. 1q11–21 (lamin A/C [5]),
3p25 (caveolin-3 [6,7], 6q23, 5q31, and 7q (neuromuscular
disorders—gene location, September 2001). At present, nine
AR forms have been mapped and, with the exception of
LGMD2H at 9q31–33 [8] and LGMD2I at 19q13.3 [9], all
the others have had their protein products identified. Four of
them, mapped at 17q21, 4q12, 13q12, and 5q33, encode
respectively for a-sarcoglycan (a-SG), h-SG, g-SG, and y-
SG, which are glycoproteins of the sarcoglycan sub-com-
plex of the dystrophin–glycoprotein complex (DGC), which
plays an important role in muscle fiber integrity [10,11].
Mutations in these genes cause, respectively, LGMD2C, 2D,
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2E, and 2F and constitute a distinct subgroup of LGMDs,
the sarcoglycanopathies [12–23]. The three other identified
forms are LGMD2B at 2p31, coding for dysferlin [24–26];
LGMD2A at 15q15.1, coding for calpain-3 [27–29] and
LGMD2G at 17q11–12, coding for telethonin [22,23]. In
addition to the mechanical and structural function of the
DGC, it has been recently shown that this complex might
play a role in cellular communication [30] as well as interact
with the sarcomeric network, through the binding of dys-
trophin to F-actin [see revision in [31]].
Telethonin is a sarcomeric protein of 19 kDa possibly
localized to the Z-disc of adult striated skeletal and cardiac
muscles, where it interacts with the protein titin [32]. The
sarcomere is the unit of skeletal and cardiac muscle con-
traction. In the past few years, there have been major
advances in the elucidation of the role of skeletal and
cardiac muscle proteins, and mutations in several sarcomeric
proteins such as actin [33], tropomosin 3 and 2 [34,35],
Troponin T1 [36], and myotilin [4] were shown to cause
human muscle diseases.
Recently, we have shown that mutations in the telethonin
gene cause LGMD2G, a relatively mild form of autosomal
recessive LGMD, originally mapped in three Brazilian
families. This was confirmed through immunohistochemis-
try and Western blot analysis using an anti-telethonin anti-
body in muscle of affected patients that presented no protein
expression [22,23].
The protein a-actinin is localized in the Z-disk of the
sarcomere [37], while the recently identified myotilin is a
57-kDa cytoskeletal protein, with two Ig-like domains
homologous to titin, which co-localizes with a-actinin in
the Z-line of the sarcomere [3].
Here, we are reporting the results from
(a) The analysis of the sarcomeric structure of muscle fibers
in patients with LGMD2G, through double co-local-
ization immunofluorescence for telethonin with the Z-
band proteins a-actinin-2 and myotilin, as well as
through electron microscopy (EM) analysis.
(b) The possible interaction of telethonin with other proteins
associated with several forms of AR-LGMD (2A, 2B,
SGpathies), Duchenne muscular dystrophy (DMD),
nemaline myopathy (NM), and spinal muscular atrophy
(SMA).
2. Patients and methods
2.1. Patients
A total of 42 myopathic patients with known mutations
were included in this investigation: 6 LGMD2G (4 fami-
lies), 9 LGMD2A, 14 LGMD2B, 2 LGMD2C, 3 LGMD2D,
2 LGMD2E, 1 LGMD2F, 3 DMD, and 2 NM. One of the
LGMD2G patients was identified through telethonin analy-
sis in a sample of 48 patients: 35 still unclassified LGMD
patients and 13 with clinical diagnosis of Kugelberg–
Welander SMA. Telethonin was also studied in 2 muscle
samples from patients with known mutations in the SMA
gene, for analysis of muscle under denervation.
The diagnosis of the patients was established through
clinical examination and course of the disease, family
history, serum creatine-kinase levels [3], DNA analysis
(linkage or screening for mutations), and/or protein studies
on muscle biopsies (dystrophin, the four sarcoglycans,
calpain-3, dysferlin, and telethonin).
2.2. Muscle biopsies
Muscle samples were obtained from bicep biopsies (for
diagnostic purposes or after informed consent) frozen in
liquid nitrogen immediately after removal and stored at  70
jC until use. Routine histological and histochemical proce-
dures were done, with staining for HE, modified Gomori
trichrome, NADH, ATPase 9.4, 4.3, and acid and alkaline
phosphatase [38]. One female patient (Table 1, #2) under-
went two muscle biopsies within a 10 year interval.
The fiber typing was determined by counting 300–500
fibers from each patient in ATPase 9.4 and 4.3 reactions,
and by calculating the percentage of type I and type II
fibers.
2.3. Protein analyses
Mouse anti-telethonin antibody was raised against a
recombinant fragment of telethonin consisting of 128 C-
terminus amino acids [39]. Additional antibodies used were:
mouse anti-titin (Novacastra and Sigma), rabbit a-actinin-2
[37], rabbit myotilin antibody [4], rabbit polyclonal N-
terminal 303-8 for dystrophin (kindly provided by J. Cham-
Table 1











1 (206) 1 male 17 13 walks, climbs stairs assisted proximal 157C>T/157C>T
2A (207) (biopsy 1) 1 female 18 6 asymptomatic – 157C>T/157C>T
2B (912) (biopsy 2) female 28 walks, climbs stairs unassisted proximal
3 (913) 1 female 22 walks, climbs stairs unassisted distal 157C>T/157C>T
4 (201) 2 female 30 15 walks, climbs stairs unassisted proximal 157C>T/157C>T
5 (208) 3 male 21 3 walks, climbs stairs assisted distal 157C>T/D637GGGG
6 (927) 4 male 27 20 walks, can not climb stairs distal and proximal 157C>T/157C>T
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berlain) and C-terminal monoclonal Dy8/6C5 for dystrophin
(kindly provided by L.V.B. Anderson), monoclonal anti-
bodies for sarcoglycans (described in Ref. [40]), calpain-3
[41], and dysferlin [42].
Immunohistochemical staining of frozen sections was
performed using double labeling reactions for a-actinin-2
and telethonin, titin or myotilin and analyzed by fluores-
cence or confocal microscopy (IBUSP), as described pre-
viously [43]. Secondary antibodies were FITC-labeled anti-
rabbit and CY3-conjugated anti mouse (Sigma).
Western blot analysis was performed using 6% or 13%
SDS-PAGE gels, and then proteins were transferred at 150
V for 1 h [44]. The blots were reacted with antibodies to
telethonin or a mix of dystrophin, dysferlin, and calpain-3.
The incubations with primary antibodies were done over-




The results of the clinical and histological analysis done
in the six LGMD2G patients are described in Table 1. With
exception of patient 5, who is a compound heterozygote
(157C>T/D637GG), the others have the same homozygous
157C>T missense mutation, which creates a premature stop
codon (Q53X) in the telethonin gene.
3.1.1. Histological analysis
Histological analysis showed a dystrophic pattern of
muscle degeneration in all six patients, including fiber size
variation, slight degree of connective tissue infiltration,
presence of high number of internally localized nuclei,
splitting, and a variable degree of rimmed vacuoles (Table
2 and Fig. 1). Only one patient (927) showed the presence of
spread ghost fibers (see HE in Fig. 4).
Histochemical analysis revealed the presence of a mosaic
pattern of type I/II fibers, with a type I predominance in two
patients (#3 and 4) and type II predominance in patient 6.
Small groups of fibers from the same type were observed in
three patients (#1, 2, 5), a type I fiber atrophy in five patients
(#1–5), while patient 6 showed type II atrophy (Table 2).
Patient #2, underwent a second muscle biopsy after 10
years, and the same anatomopathological alterations, with
a very similar degree of muscle degeneration, were seen
in both samples. The only observed difference was in
type I/II fiber proportions, with an increase in type I
predominance.
Table 2

















1 + + + + + ++ + + + 0 2/500 1/500 55/45 type I
2A + + 0 + + 0 2/200 0 52/48 type I
2B + + + + + 0 2/200 0 62/38 type I
3 + + 0 + 0 0 1/500 3/500 80/20 type I
4 + + + + + ++ + + + 0 0 8/500 66/34 type I
5 + + + + + ++ + + + 1/250 5/250 10/80 44/56 type I
6 + + 0 + + + + 1/300 3/500 0 12/88 type II
Fig. 1. Histological analysis (Hematoxilin & Eosin staining) and histochemical analysis (ATPase 9.4) in the 6 LGMD2G patients. Magnification: HE  200,
ATPase  100.
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3.1.2. Immunohistochemical analysis
In normal controls, telethonin immunofluorescence anal-
ysis showed a strong sarcomeric labeling pattern, with the
majority of myonuclei also positively labeled (Fig. 2). Both
type I and type II fibers were equally labeled.
Muscle from all 6 LGMD2G patients showed a total
absence of telethonin in the sarcomeric network, but some
labeling in the nucleus (Fig. 2). Double immunofluores-
cence analysis for a-actinin 2 and telethonin showed a
cross-striation pattern in muscle fibers with the first anti-
body but no labeling with the second one (Fig. 3A).
Myotilin IF analysis also showed a sarcomeric pattern in
their muscle fibers (Fig. 3B).
Fig. 3. (A) Double immunofluorescence for a-actinin-2 and telethonin in a
normal control and in one LGMD2G patient (#2); (B) double IF for myo-
tilin and telethonin, and the homogeneous reaction for titin (sigma anti-
body); (C) EM of the same sample of muscle, showing the maintenance of
the sarcomeric structure ( 40,000).
Fig. 4. Double immunofluorescence of a-actinin-2 and titin (Novacastra
antibody) in two LGMD2G patients, showing the positive titin pattern with
a mosaic of type II fibres with higher labeling for titin (magnification:
 200).
Fig. 5. Immunohistochemical analysis for dystrophin and two sarcoglycans,
as well as multiplex western blot for dystrophin, dysferlin and calpain-3 in
the LGMD2G patients, showing normal distribution and quantity of the
proteins.
Fig. 2. Immunofluorescence analysis using anti-telethonin antibodies in
LGMD2G patients, as compared to a normal control. Magnification:  400.
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The analysis of titin through two antibodies showed a
positive IF pattern with both in LGMD2G patients (Fig. 3),
with a mosaic pattern of more positively labeled type II
fibers through the antibody from Novacastra (Fig. 4).
Analysis for sarcolemmal proteins showed normal
expression of dystrophin, sarcoglycans, dysferlin, and cal-
pain-3 proteins in the LGMD2G patients (Fig. 5).
3.1.3. Ultrastructural analysis
Ultrastructural analysis confirmed the maintenance of the
sarcomeric architecture integrity in the LGMD2G patients
(Fig. 3C).
3.2. Other forms of neuromuscular disorders
The analysis of telethonin on muscle biopsies from
patients with LGMD2A, LGMD2B, SGpathies, and DMD
showed a positive sarcomeric pattern in all and a band of the
expected MW by Western blot analysis (Fig. 6B). In
addition, in muscle fibers from patients with NM, telethonin
was clearly present in the rods while in SMA patients, also a
normal telethonin IF pattern was observed (Fig. 6A).
4. Discussion
Mutations in the telethonin gene are apparently rare. As
stated in our previous report, although the Brazilian pop-
ulation is highly miscigenated, an identical haplotype asso-
ciated with the mutation 157C>T was found in three of the
four families, suggesting a founder effect [23].
Telethonin, which is the 12th most abundant nuclear
transcript in adult skeletal muscle [39], has been shown to
be one of the substrates of titin, the giant 3–4 MDa
sarcomeric protein. Titin acts as a molecular ruler for the
assembly of the sarcomere by providing spatially defined
binding sites for other sarcomeric proteins over the entire
length of the half-sarcomere [45]. After its activation
through phosphorylation and Ca2 + /calmodulin binding,
titin was shown to phosphorylate the C-terminal domain
of telethonin [46]. In addition, it was suggested that the N-
terminal region of titin could adopt a closed conformation,
which would block the telethonin binding site. In vivo,
phosphorylation of the multiple serine–proline phosophor-
ylation sites by developmentally controlled kinases could be
the modulation factor controlling titin–telethonin interac-
tions [32].
Telethonin also has putative phosphorylation sites in its
C-terminal region [39], and the dual phosphorylation of
both titin and telethonin might be important in controlling
the interaction of both proteins. The mutations identified in
our LGMD2G patients lead to the disruption of this func-
tionally important region of telethonin [23], resulting in the
absence of the telethonin protein in muscle fibers from all
six studied LGMD2G patients. However, titin was clearly
retained, as observed through the positive pattern on IF.
Only one titin gene has been identified in the human
genome. This gene has several isoforms produced by alter-
native splicing which are responsible for individual diversity
of distribution in human muscles [47]. Therefore, the
mosaic pattern of titin observed in our patient with a
monoclonal titin antibody could reflect the recognition of
an epitope in the C-terminal region, in a similar way to the
one seen with myosin isoforms and fiber typing, although
the possibility that the differential staining could be due to
the accessibility of the epitopes rather than truly differ-
entially expressed isoforms cannot be ruled out.
In cardiac myocytes, it has been shown that both the titin
Z1–Z2 domains and telethonin (titin-cap) are required for
the structural integrity of sarcomeres. A severe myofibril
disruption is observed after over expression of either mol-
ecule, suggesting that their interaction is critical in titin
filament-regulated sarcomeric assembly [32]. In our
LGMD2G patients, immunofluorescence analysis for a-
actinin-2 and myotilin, two proteins from the Z-disk of
the sarcomere, showed a cross-striation pattern, suggesting
that at least part of this myofibrilar structure is retained.
Ultrastructural analysis confirmed the maintenance of the
sarcomeric architecture in our telethonin deficient patients.
These observations suggest that muscle degeneration and
Fig. 6. (A) Double Telethonin and a-actinin-2 analysis in patients with other forms of MD (LGMD2B and sarcoglycanopathy 2D), in a patient with nemaline
myopathy, showing the high concentration of telethonin in the rods, and the normal distribution of telethonin in a SMA patient. (B) Western blot analysis in
some other forms of LGMD, as compared to control (C) and LGMD2G patients. T = Telethonin; M=myosin content in the ponceau pre-stained blot.
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weakness in LGMD2G patients with null mutations in the
telethonin gene are more likely to occur due to a functional
defect than to an alteration in the sarcomeric structure. On
the other hand, the presence of rimmed vacuoles in the
muscle fibers from these patients might be due to focal
regions of sarcomeric degeneration.
Mues et al. [45] demonstrated that telethonin localizes to
the nascent Z-disk in cultured myocytes. Here, the analysis
of muscle fibers from patients with NM demonstrated that
telethonin was clearly present in the rods, which are formed
by proteins from the Z-band of the sarcomere [48]. There-
fore, the presence of telethonin in the rods as well as its co-
localization with a-actinin and myotilin confirm the pres-
ence of telethonin in the Z-disk also in the mature muscle.
In our previous report, we have shown an identical
haplotype associated with the mutation 157C>T in three
of the four LGMD2G families. Families 1 and 2 (Table 2)
are inbreed and of Negroid descent, while both parents in
family 3, in which the mutation is in homozygosity, have
Italian ancestry [23]. Therefore, although these three fami-
lies apparently have distinct origin, our population is highly
miscigenated and the finding of a common haplotype in
them suggests a founder effect in Brazil.
4.1. Histological characterization of LGMD2G patients
In the first histopathological description of patients with
LGMD2G, muscle biopsies showed the presence of a high
number of rimmed vacuoles [49]. The analysis of four
additional LGMD2G patients revealed that although present
in the majority of muscle samples, the rimmed vacuoles
were not the predominant histopathological marker of this
disease. A high variability in the degree of muscle degen-
eration was observed among the six patients, which did not
appear to be correlated to the clinical course.
Interestingly, the analysis of a new muscle biopsy sample
of a female patient who was asymptomatic when the first
biopsy was taken, but clearly affected 10 years later, showed
very few pathological alterations, suggesting that no gross
muscle degeneration occurs with time in telethonin-deficient
patients.
Muscle fiber composition showed a variability of fiber
typing. Five of the patients had a significant type I predom-
inance, while in one patient, a very high type II predom-
inance was observed, thus suggesting no direct correlation
with the primary gene defect. As observed in the present
patients, small areas of atrophy and fiber type predominance
are characteristic of denervation. However, this can also be
the result of the splitting of larger fibers, which is very
common in the dystrophic process [38]. Therefore, caution
should be taken in interpreting these type of results.
The analysis of the amount of the telethonin transcript in
a number of mice muscles of different types, including
slow-twitch postural (soleus) and fast-twitch (EDL)
muscles, showed that there is no statistically different levels
of expression between muscle of different fiber type com-
position [50]. In the present study, both type I and type II of
human mature fibers expressed the same pattern of tele-
thonin. Therefore, the apparent increase in proportion of
type I fibers in five of the six patients (and also common in
congenital myopathies [38]) appears not to be related to a
preferential expression of telethonin in a specific type of
fiber.
On the other hand, in one family, only proximal weak-
ness occurred, while in three families, both distal and
proximal involvement were observed. A mixed pattern of
proximal and distal pattern of weakness may also be present
in other forms of LGMD, such as the proximal LGMD2B
and distal Miyoshi Myopathy, both associated with muta-
tions in the dysferlin gene [25,26].
4.2. Denervation
Mason et al. [50] have shown that the mouse telethonin
transcript is down-regulated in response to denervation.
Short-term denervation (2 days) was sufficient to lead to a
50% fall in the level of telethonin in the muscle of the
denervated animals, suggesting that innervation and/or mus-
cular activity was necessary for the maintenance of tele-
thonin expression. Our analysis of telethonin in muscle
biopsies from SMA patients (genetically denervated)
showed a sarcomeric pattern of labeling which did not differ
from normal controls, suggesting no telethonin alteration in
these cases.
4.3. Interactions
In our first studies, the observation of normal dystrophin
and a-sarcoglycan staining in the muscle of LGMD2G
patients [23] would indicate that the product of this gene
apparently did not interact with the DGC. Here, we confirm
that muscle from patients with LGMD2G showed normal
expression of dystrophin, the four sarcoglycans, dysferlin
and calpain-3. In addition, the analysis of telethonin on
muscle biopsies from patients with LGMD2A, LGMD2B,
SGpathies, and DMD showed normal localization, suggest-
ing that the deficiencies of calpain-3, dysferlin, sarcoglycans,
and dystrophin do not seem to alter telethonin expression.
4.4. Differential diagnosis
Since our LGMD2G patients showed a broad range of
phenotypes, ranging from Kugelberg–Wellander-like to typ-
ical LGMD, we screened for telethonin deficiency in muscle
biopsies from 48 patients with these phenotypes, in an
attempt to identify additional cases of LGMD2G. One addi-
tional patient (#5), with a total deficiency of telethonin was
detected. Complementary DNA studies detected homozygos-
ity for the 157C>T/157C>T mutation in his telethonin gene.
In a recent report from our Center, we studied a total of
153 LGMD families (118 classified and 35 unclassified) by
DNA and protein analysis [51]. Considering that in four of
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these families the patients are affected by LGMD2G, the
frequency of telethonin deficiency is estimated as approx-
imately 2.5% of all cases of LGMD in our population.
In conclusion, our data show that muscles from patients
with LGMD2G have a normal expression for the proteins
dystrophin, sarcoglycans, dysferlin, calpain-3, and titin, and
the primary deficiencies of that proteins do not seem to alter
telethonin expression. The observed maintenance of the
sarcomeric architecture suggests that the primary absence
of telethonin apparently has no effect on the formation and
composition of the sarcomere in the LGMD2G patients.
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